CD4+ T-cell epitope determination using unexposed human donor peripheral blood mononuclear cells

Area of Science:

• Immunology
• Protein Engineering
• Therapeutics Development

Background:

• Protein therapeutic engineering can create new T-cell epitopes.
• Existing assays for T-cell epitopes require exposed donors, limiting novel protein assessment.
• Current methods like HLA binding prediction need validation through in vitro presentation assays.

Purpose of the Study:

• To develop and validate a novel assay for detecting primary T-cell responses to engineered protein epitopes.
• To enable T-cell epitope identification in humans using unexposed donors.
• To assess the utility of this assay for immunoregulatory applications.

Main Methods:

• A dendritic cell-based assay was developed to identify CD4+ T-cell epitopes.
• The assay utilizes peripheral blood lymphocytes from unexposed donors for de novo priming.
• Predicted T-cell epitopes were confirmed using cells from exposed donors.

Main Results:

• The assay successfully identified CD4+ T-cell epitopes in novel proteins.
• The major T-cell epitope identified was associated with HLA-DRB1*15 expression.
• The assay demonstrated accurate identification of primary T-cell epitopes through in vitro de novo priming.

Conclusions:

• This dendritic cell-based assay is a powerful tool for identifying T-cell epitopes in novel proteins.
• The assay enables the assessment of T-cell responses to engineered proteins in humans.
• It supports the development of safer protein therapeutics and immunoregulatory strategies.